Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 15;67(6):e0042323.
doi: 10.1128/aac.00423-23. Epub 2023 May 24.

Novel Non-Hot Spot Modification in Fks1 of Candida auris Confers Echinocandin Resistance

Milena Kordalewska  1 , Geselle Cancino-Prado  1 , João Nobrega de Almeida Júnior  2   3 , Igor Brasil Brandão  4 , Renata Tigulini de Souza Peral  5 , Arnaldo L Colombo  2 , David S Perlin  1
Affiliations

Novel Non-Hot Spot Modification in Fks1 of Candida auris Confers Echinocandin Resistance

Milena Kordalewska et al. Antimicrob Agents Chemother. .

Abstract

We determined the echinocandin susceptibility and FKS1 genotypes of 13 clinical isolates of Candida auris that were recovered from 4 patients at a tertiary care center in Salvador, Brazil. Three isolates were categorized as echinocandin-resistant, and they harbored a novel FKS1 mutation that led to an amino acid change W691L located downstream from hot spot 1. When introduced to echinocandin-susceptible C. auris strains by CRISPR/Cas9, Fks1 W691L induced elevated MIC values to all echinocandins (anidulafungin, 16 to 32×; caspofungin, >64×; micafungin, >64×).

Keywords: Candida; Candida auris; FKS1; anidulafungin; antifungal resistance; antifungal susceptibility testing; caspofungin; echinocandin resistance; echinocandins; micafungin.

PubMed Disclaimer

Conflict of interest statement

The authors declare a conflict of interest. A.L.C. serves on advisory boards/educational programs of Amgen, Ache, Biotoscana-United Medical, Eurofarma, Mundipharma, Gilead, and Pfizer. D.S.P. receives funding from the U.S. National Institutes of Health (NIH) and contracts with Merck, Regeneron and Pfizer. He serves on advisory boards for N8 Medical and Scynexis. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Perlin DS. 2015. Mechanisms of echinocandin antifungal drug resistance. Ann N Y Acad Sci 1354:1–11. doi: 10.1111/nyas.12831. - DOI - PMC - PubMed
    1. Watkins RR, Gowen R, Lionakis MS, Ghannoum M. 2022. Update on the pathogenesis, virulence, and treatment of Candida auris. Pathog Immun 7:46–65. doi: 10.20411/pai.v7i2.535. - DOI - PMC - PubMed
    1. Carolus H, Pierson S, Munoz JF, Subotic A, Cruz RB, Cuomo CA, Van Dijck P. 2021. Genome-wide analysis of experimentally evolved Candida auris reveals multiple novel mechanisms of multidrug resistance. mBio 12. doi: 10.1128/mBio.03333-20. - DOI - PMC - PubMed
    1. Hirayama T, Miyazaki T, Sumiyoshi M, Ito Y, Ashizawa N, Takeda K, Iwanaga N, Takazono T, Yamamoto K, Izumikawa K, Yanagihara K, Makimura K, Tsukamoto K, Kohno S, Mukae H. 2023. Echinocandin resistance in Candida auris occurs in the murine gastrointestinal tract due to FKS1 mutations. Antimicrob Agents Chemother 67:e0124322. doi: 10.1128/aac.01243-22. - DOI - PMC - PubMed
    1. CLSI. 2017. Reference method for broth dilution antifungal susceptibility testing of yeasts. 4th ed CLSI standard M27. Clinical and Laboratory Standards Institute, Wayne, PA.

Publication types

LinkOut - more resources